# SIGA Technologies Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/SIGA Technologies Inc). ## Overview SIGA Technologies is a U.S.-based pharmaceutical company focused on developing and commercializing treatments for orthopoxvirus infections, centered on its oral antiviral product TPOXX® (tecovirimat). The company’s business combines drug development, regulatory maintenance, intellectual property management, and third-party manufacturing and distribution arrangements across the United States and international markets. ## Products & services • TPOXX® (tecovirimat) oral antiviral • Orthopoxvirus treatment development • Regulatory and medical countermeasure support • International commercialization and supply arrangements • Patent and trademark portfolio management - **TPOXX® oral antiviral** (80%) — Commercial sales and supply of oral TPOXX® for orthopoxvirus-related indications and government stockpiles. - **Supportive services** (10%) — Contract-related supportive services tied to product delivery, performance obligations, and customer programs. - **International sales and promotion arrangements** (10%) — Sales and commercialization activity outside the United States through international contract structures. - TPOXX® (tecovirimat) oral antiviral - Orthopoxvirus treatment development - Regulatory and medical countermeasure support - International commercialization and supply arrangements - Patent and trademark portfolio management ## Customers SIGA sells primarily to government customers and public-health procurement channels that buy TPOXX® for biodefense preparedness and outbreak response. It also serves international counterparties and, through promotion agreements, reaches non-U.S. markets where regulatory approvals and procurement pathways differ by country. - **U.S. Government / BARDA** (primary) — Buys oral TPOXX® under government supply contracts for preparedness and response use. - **International government and public-health customers** (primary) — Purchases oral TPOXX® for national stockpiles or outbreak response through country-specific arrangements. - **Promotion and distribution counterparties** (secondary) — Commercial partners that market or facilitate sales outside the U.S. under defined territory agreements. - U.S. government buyers for biodefense stockpiling and delivery contracts - International public-sector customers for oral TPOXX® supply - Government health agencies seeking outbreak-response antivirals - Contract counterparties that manage foreign sales and promotion - Regulatory and procurement bodies that influence purchase timing ## Geography SIGA is headquartered in the United States, where it retains sales and marketing rights for oral TPOXX® and manages core regulatory responsibilities. Outside the U.S., the company relies on international promotion and supply arrangements, with sales activity spanning multiple foreign jurisdictions and one-country deliveries in reported periods. - United States is the core market and operating base - U.S. government contracts are a key demand channel - International sales are handled through country-specific deliveries - Non-U.S. commercialization depends on local regulatory approvals - Manufacturing is outsourced to third-party CMOs rather than owned plants ## Strategy SIGA’s strategy centers on maintaining and extending the commercial and regulatory position of TPOXX® while preserving intellectual property protection across major markets. The company also depends on third-party manufacturing and international promotion structures, so execution quality in supply, regulatory compliance, and contract performance is central to its business model. - **Defend and expand TPOXX® intellectual property** (medium-term) — Patent and trademark protection supports exclusivity and commercial durability. - **Preserve regulatory access across jurisdictions** (medium-term) — Market access depends on maintaining approvals and meeting local requirements. - **Reliably execute outsourced manufacturing and delivery** (short-term) — The company depends on CMOs for production, packaging and testing. - Protect and extend TPOXX® patent and trademark coverage - Maintain regulatory approvals in the U.S. and abroad - Use CMOs to avoid owning manufacturing infrastructure - Support government and international biodefense demand - Manage supply-chain execution and contract delivery timing ## Risks SIGA’s business is concentrated in a single product and depends on government procurement, regulatory approvals, and third-party manufacturing execution. Key risks include supply-chain disruption, cyber incidents, patent or approval setbacks, and the possibility that international biodefense demand develops more slowly than expected. - **Dependence on U.S. government contracts** [high] — A large share of demand is tied to BARDA and other public-sector procurement. - **Third-party manufacturing and supply-chain disruption** [high] — SIGA does not own manufacturing infrastructure and relies on CMOs. - **Regulatory approval risk outside the United States** [medium] — Foreign commercialization requires country-specific approvals and compliance. - **Cybersecurity and data integrity incidents** [medium] — A breach could affect clinical, manufacturing or quality records. - **Patent and trademark protection challenges** [high] — Exclusivity depends on maintaining broad IP coverage across jurisdictions. - Single-product concentration increases dependence on TPOXX® demand - Government contract timing and renewal risk can affect revenue visibility - CMO dependence creates supply, quality and delivery execution risk - Foreign approvals and labeling rules can delay international sales - Cybersecurity failures could disrupt clinical, quality or manufacturing data ## Accounting SIGA’s most important accounting judgment is revenue recognition, including over-time recognition for contract performance obligations and the timing of product sales and supportive services. Reported results can also move quarter to quarter because international contract timing, delivery schedules, and estimate updates affect when revenue and related costs are recognized. - **Revenue recognition over time** — Affects timing of revenue, cost of sales and supportive services - **Cumulative catch-up adjustments** — Can create volatility in reported quarterly revenue and margins - **International sales timing** — Can shift revenue between quarters and between U.S. and foreign markets - Revenue recognition over time for contract performance obligations - Quarterly estimate updates can change revenue and cost recognition - International sales timing affects period-to-period comparability - Supportive services revenue may be recognized separately from product sales - Third-party manufacturing and contract terms influence cost allocation --- *Last updated: 2026-04-29T04:55:20.284355+00:00*